Sarepta医疗

Citigroup maintains Sell rating for Sarepta, raises PT to $9 from $8.

Sarepta's 15-min chart triggers MACD Death Cross, Bollinger Bands Narrowing

Sarepta's KDJ Death Cross and Bearish Marubozu Signal Bearish Trend

Sarepta's 15-min chart triggers MACD Death Cross and KDJ Death Cross.

Sarepta:HC Wainwright Raises Sell Rating to $5, PT Up to $5

Catalyst<ul> <li>Most analysts rate SRPT Buy or Strong Buy, showing broad institutional optimism.</li> <li>Medium and Large institutional flows show positive net inflow trends.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a weak state, and we need to pay attention to the risk of decline.</li> <li>Bearish signals are obviously dominant (5 bearish vs 0 bullish).</li> <li>At least one major firm maintains a Strong Sell rating, reflecting significant concerns about SRPT's outlook.</li></ul>

Key Factors

Wells Fargo cut SRPT's price target to $38, signaling a potential 128.02% upside from recent levels despite broader analyst caution.HC Wainwright raised SRPT's sell rating to $5, increasing its price target to $5.

SRPT News